Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Daiichi Sankyo Company, Limited    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
  • Sales forecast by analysts have been recently revised upwards.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 6087 JPY
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at JPY 8180.
  • The company's enterprise value to sales, at 4.73 times its current sales, is high.
  • With an expected P/E ratio at 43.5 and 57.26 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
DAIICHI SANKYO COMPANY, LIM..7.87%44 657
JOHNSON & JOHNSON2.10%390 914
ROCHE HOLDING AG10.05%298 571
NOVARTIS3.81%217 737
MERCK AND COMPANY-9.30%210 018
PFIZER-7.53%198 398
NOVO NORDISK AS14.43%150 219
BRISTOL-MYERS SQUIBB COMPAN..2.37%146 698
ABBVIE INC.6.43%139 349
AMGEN INC.-7.51%131 020
ELI LILLY AND COMPANY8.04%128 706
ASTRAZENECA PLC-0.43%127 958
SANOFI4.33%126 519
GLAXOSMITHKLINE-7.25%105 721
BAYER AG2.54%79 158
ALLERGAN PLC4.00%65 386
More Results
Financials (JPY)
Sales 2020 980 B
EBIT 2020 136 B
Net income 2020 114 B
Finance 2020 362 B
Yield 2020 0,92%
P/E ratio 2020 43,5x
P/E ratio 2021 57,3x
EV / Sales2020 4,73x
EV / Sales2021 4,59x
Capitalization 4 999 B
Upcoming event on DAIICHI SANKYO COMPANY, LI
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes